Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. PAAB Q&A
  3. Non-product branded APS, pre-NOC teasers
  4. Branded and Unbranded APS in Conference Setting
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

Branded and Unbranded APS in Conference Setting

Scheduled Pinned Locked Moved Non-product branded APS, pre-NOC teasers
4 Posts 2 Posters 807 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • G Offline
    G Offline
    georgian21
    wrote on last edited by
    #1

    In a conference setting, is it possible to display unbranded Disease State advertising (helping educate about the disease prior to the launch of Drug A) along with branded content for Drugs B and C (which are already in the market)?

    Jennifer CarrollJ 1 Reply Last reply
    0
    • G georgian21

      In a conference setting, is it possible to display unbranded Disease State advertising (helping educate about the disease prior to the launch of Drug A) along with branded content for Drugs B and C (which are already in the market)?

      Jennifer CarrollJ Offline
      Jennifer CarrollJ Offline
      Jennifer Carroll
      wrote on last edited by
      #2

      Hey @georgian21

      As a general rule of thumb, branded and unbranded should be separate and distinct. The difficulty in having unbranded content presented in the same booth as branded content is that it has the potential to create an association between the two (i.e. it brands the unbranded pieces) which is not generally permitted due to the potential for off-label implications.

      G 1 Reply Last reply
      0
      • Jennifer CarrollJ Jennifer Carroll

        Hey @georgian21

        As a general rule of thumb, branded and unbranded should be separate and distinct. The difficulty in having unbranded content presented in the same booth as branded content is that it has the potential to create an association between the two (i.e. it brands the unbranded pieces) which is not generally permitted due to the potential for off-label implications.

        G Offline
        G Offline
        georgian21
        wrote on last edited by
        #3

        @jennifer-carroll Thank you.

        Just to clarify, Drug A (unbranded) and Drugs B/C (branded) would belong to different disease areas.

        Would that change the PAAB ruling?

        Jennifer CarrollJ 1 Reply Last reply
        0
        • G georgian21

          @jennifer-carroll Thank you.

          Just to clarify, Drug A (unbranded) and Drugs B/C (branded) would belong to different disease areas.

          Would that change the PAAB ruling?

          Jennifer CarrollJ Offline
          Jennifer CarrollJ Offline
          Jennifer Carroll
          wrote on last edited by
          #4

          Hey @georgian21

          This does give us pause to consider the nuance of the scenario. The main concern is separation. When we put unbranded content with branded, it creates an association that brands everything. Even if it is a separate therapeutic area, the question is, can we ensure that there is no suggestion that the product has implications (e.g. safety/efficacy) in that therapeutic area? We’d also have to consider the therapeutic areas as some are more closely related than others.

          Example:
          - Drug A (renal or CV drug); Drug B/C (diabetes)
          - Drug A (lipid drug); Drug B/C (HIV)

          This type of question might be more suited for an opinion so that we may assess the intricacies.

          1 Reply Last reply
          0
          Reply
          • Reply as topic
          Log in to reply
          • Oldest to Newest
          • Newest to Oldest
          • Most Votes


          • Login

          • Don't have an account? Register

          • Login or register to search.
          • First post
            Last post
          0
          • Categories
          • Recent
          • Tags
          • Popular
          • Users
          • Groups